DRUG (DRUG) Stock Price & Analysis
DRUG (DRUG) rose 0.06% to USD 71.33 as of July 25, 2026 at 19:05 UTC, according to Nexqual real-time market data.
DRUG last closed at USD 71.29; the session ranged USD 70.56–73.5 on volume of 345,125 shares. Market capitalization is $699.89M, with a 52-week range of USD 31.8–123.75 (NCM). Source: Nexqual, July 25, 2026 at 19:05 UTC.
Key Statistics (as of July 25, 2026 at 19:05 UTC)
| Price | USD 71.33 |
|---|---|
| Change | ▲ 0.06% (up) |
| Previous Close | USD 71.29 |
| Open | USD 71.97 |
| Day Range | USD 70.56 – 73.5 |
| 52-Week Range | USD 31.8 – 123.75 |
| Volume | 345,125 shares |
| Market Cap | $699.89M |
| Exchange | NCM |
Technical Analysis (DRUG)
Nexqual's technical model rates DRUG "SELL" based on 1 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 19:05 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 48.56 (neutral) |
| vs SMA50 | Below (USD 72.46) |
| MACD | 0.97 (positive) |
Analyst Ratings (DRUG)
Wall Street analysts rate DRUG "None" based on 3 analysts, with a mean price target of USD 166.74 (range USD 142.31–214.87), per Nexqual as of July 25, 2026 at 19:05 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 166.74 |
| High Target | USD 214.87 |
| Low Target | USD 142.31 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (DRUG)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -1.64 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.09 vs est -1.26 ▲ beat |
| 2025-12-31 | USD -0.97 vs est -1.19 ▲ beat |
| 2025-09-30 | USD -0.58 vs est -1 ▲ beat |
| 2025-06-30 | USD -0.74 vs est -0.88 ▲ beat |
Source: Nexqual, July 25, 2026 at 19:05 UTC.
Financials & Fundamentals (DRUG)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -15.02% |
| Debt / Equity | 0.03 |
| Current Ratio | 81.48 |
| Total Cash | $309.69M |
| Total Debt | $82,130 |
| Free Cash Flow | $-13.10M |
Source: Nexqual, July 25, 2026 at 19:05 UTC.
Financial Health Score (DRUG)
Nexqual rates DRUG's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 19:05 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $310M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$20M |
| Efficiency | Critical — ROE -15%, ROA -10.4% |
Ownership (DRUG)
| Insider Ownership | +12.00% |
|---|---|
| Institutional Ownership | +93.00% |
| Shares Outstanding | 9.81M |
| Float | 5.13M |
| Short % of Float | +12.64% |
Source: Nexqual, July 25, 2026 at 19:05 UTC.
Leadership (DRUG)
DRUG is led by Ian McDonald (age 37), Co-Founder, CEO, President & Director, per Nexqual as of July 25, 2026 at 19:05 UTC.
| Co-Founder, CEO, President & Director | Ian McDonald (age 37) |
|---|---|
| Chief Science Officer & Director | Jan Torleif Pedersen M.Sc. (age 60) |
| COO & Senior Scientific Officer | Alex Vasilkevich (age 36) |
Major Backers & Investors (DRUG)
Notable institutional backers of DRUG include Janus Henderson Group PLC, Cormorant Asset Management, LP, Vivo Capital, LLC, according to Nexqual as of July 25, 2026 at 19:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Janus Henderson Group PLC | 13.2% |
| Cormorant Asset Management, LP | 10.88% |
| Vivo Capital, LLC | 5.73% |
| Braidwell LP | 5.55% |
| Adage Capital Partners GP L.L.C. | 5.09% |
| Vestal Point Capital, LP | 5.06% |
| Driehaus Capital Management, LLC | 4.44% |
| Perceptive Advisors Llc | 3.88% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.99% |
Source: Nexqual, July 25, 2026 at 19:05 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| QNRX | Quoin Pharmaceuticals, Ltd. | USD 4.28 | ▼ 2.17% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.26 | ▼ 7.96% |
| VRAX | Virax Biolabs Group Limited | USD 3.19 | ▼ 12.36% |
| BIVI | BioVie Inc. | USD 1.37 | ▲ 2.24% |
| MEGL | Magic Empire Global Limited | USD 1.15 | ▲ 0.17% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 19:05 UTC. This page is informational and not investment advice.